Cargando…

New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event

Atherosclerosis is considered an irreversible process, with crucial contribution of inflammation and immune cells. Impact of cancer immunotherapy on a partly immune-driven disease, such as atherosclerosis, is poorly understood, but preclinical models suggest its worsening on programmed death/ligand-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lamberti, Giuseppe, Gelsomino, Francesco, Brocchi, Stefano, Poerio, Antonio, Melotti, Barbara, Sperandi, Francesca, Gargiulo, Mauro, Borghi, Claudio, Fiorentino, Michelangelo, Ardizzoni, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383634/ https://www.ncbi.nlm.nih.gov/pubmed/32782484 http://dx.doi.org/10.1177/1758835920913801

Ejemplares similares

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Macrophages in Atheromatous Plaque Developmental Stages
por: von Ehr, Alexander, et al.
Publicado: (2022)

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer
por: Parisi, Claudia, et al.
Publicado: (2020)

Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
por: De Giglio, Andrea, et al.
Publicado: (2022)

Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge
por: van der Westhuizen, Andre, et al.
Publicado: (2022)

The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

The site-specific distribution of atheromatous plaques in the coronary arteries
por: Wasilewski, Jarosław, et al.
Publicado: (2023)

Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies
por: Kim, Migang, et al.
Publicado: (2023)

Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study
por: Ricci, Costantino, et al.
Publicado: (2020)

Progression and Observational Frequency of Atheromatous Plaques in Autopsied Coronary Arteries
por: Lee, Wang-Soo, et al.
Publicado: (2009)

Expression of NPP1 is regulated during atheromatous plaque calcification
por: Nitschke, Yvonne, et al.
Publicado: (2011)

Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes
por: Di Federico, Alessandro, et al.
Publicado: (2022)

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
por: Cinausero, Marika, et al.
Publicado: (2019)

The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy
por: De Giglio, Andrea, et al.
Publicado: (2022)

Identification of Periopathogens in Atheromatous Plaques Obtained from Carotid and Coronary Arteries
por: Pavlic, Verica, et al.
Publicado: (2021)

Association between Small Intestinal Bacterial Overgrowth and Subclinical Atheromatous Plaques
por: Dong, Changhao, et al.
Publicado: (2022)

Is electrical neuromodulation able to affect the extent and stability of coronary atheromatous plaques?
por: Sanderson, John E, et al.
Publicado: (2023)

Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma
por: Comito, Francesca, et al.
Publicado: (2022)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
por: Gelsomino, Francesco, et al.
Publicado: (2020)

Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
por: Gelsomino, Francesco, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Microbial Diversity Similarities in Periodontal Pockets and Atheromatous Plaques of Cardiovascular Disease Patients
por: Serra e Silva Filho, Wagner, et al.
Publicado: (2014)

Presence of Periodontopathic Bacteria DNA in Atheromatous Plaques from Coronary and Carotid Arteries
por: Szulc, Malgorzata, et al.
Publicado: (2015)

Motion synchronisation patterns of the carotid atheromatous plaque from B-mode ultrasound
por: Golemati, Spyretta, et al.
Publicado: (2020)

Calcification patterns in femoral and carotid atheromatous plaques: A comparative morphometric study
por: Cosarca, Mircea Catalin, et al.
Publicado: (2021)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
por: Elkrief, Arielle, et al.
Publicado: (2023)

Synopsis of Biomarkers of Atheromatous Plaque Formation, Rupture and Thrombosis in the Diagnosis of Acute Coronary Syndromes
por: Udaya, Ralapanawa, et al.
Publicado: (2022)

Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study
por: Yang, Jin, et al.
Publicado: (2022)

Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer
por: Cavazzoni, Andrea, et al.
Publicado: (2020)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
por: Jimbu, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ntru2d61rt1semh9vmh02a7075